BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ASC30 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ASC30\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07743463-211@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:ASC30: Phase 3 readout est. (NCT07743463)
DESCRIPTION:ASC30\, phase 3\, Obesity.\nStudy: A Study of Once-daily Oral A
 SC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesit
 y or Overweight With Weight-Related Comorbidities\nEstimated primary compl
 etion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/asc
 30#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7743463
URL:https://assetmemo.bio/drug/asc30#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743450-211@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:ASC30: Phase 3 readout est. (NCT07743450)
DESCRIPTION:ASC30\, phase 3\, Obesity.\nStudy: A Study of Once-daily Oral A
 SC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesit
 y or Overweight With Type 2 Diabetes\nEstimated primary completion: July 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/asc30#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07743450
URL:https://assetmemo.bio/drug/asc30#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
